A comparison of side-effects and quality-of-life in patients operated on for prostate cancer with and without salvage radiation therapy

References

• Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66(2):243–250.
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–2027.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013;190(2):441–449.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–439.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Vidal AC, Howard LE, et al. Race and risk of metastases and survival after radical prostatectomy: results from the SEARCH database. Cancer. 2017;123(21):4199–4206.
   PubMed Web of Science ®Google Scholar
• Bartkowiak D, Thamm R, Bottke D, et al. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. Acta Oncol. 2018;57(3):362–367.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–629.
   PubMed Web of Science ®Google Scholar
• Feng M, Hanlon AL, Pisansky TM, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68(5):1417–1423.
   PubMed Web of Science ®Google Scholar
• Wallis CJD, Glaser A, Hu JC, et al. Survival and complications following surgery and radiation for localized prostate cancer: an international collaborative review. Eur Urol. 2018;73(1):11–20.
   PubMed Web of Science ®Google Scholar
• Nath SK, Sandhu AP, Rose BS, et al. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78(2):435–441.
   PubMed Web of Science ®Google Scholar
• Katayama S, Striecker T, Kessel K, et al. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial. Int J Radiat Oncol Biol Phys. 2014;90(4):926–933.
   PubMed Web of Science ®Google Scholar
• Wilson KA, Dowling AJ, Abdolell M, et al. Perception of quality of life by patients, partners and treating physicians. Qual Life Res. 2000;9(9):1041–1052.
   PubMed Web of Science ®Google Scholar
• Sonn GA, Sadetsky N, Presti JC, et al. Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol. 2013;189(1 Suppl):S59–S65.
   PubMed Web of Science ®Google Scholar
• Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer. 1994;74(9):2520–2532.
   PubMed Web of Science ®Google Scholar
• Fransson P, Tavelin B, Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy-induced side effects. Support Care Cancer. 2001;9(3):187–198.
   PubMed Web of Science ®Google Scholar
• Cortes-Gonzalez JR, Castellanos E, Sandberg K, et al. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy. Int J Oncol. 2013;42(1):109–117.
   PubMed Web of Science ®Google Scholar
• Alsadius D, Olsson C, Pettersson N, et al. Patient-reported gastrointestinal symptoms among long-term survivors after radiation therapy for prostate cancer. Radiother Oncol. 2014;112(2):237–243.
   PubMed Web of Science ®Google Scholar
• Raziee H, Berlin A. Gaps between Evidence and practice in postoperative radiotherapy for prostate cancer: focus on toxicities and the effects on health-related quality of life. Front Oncol. 2016;6:70.
   PubMed Web of Science ®Google Scholar
• Goenka A, Magsanoc JM, Pei X, et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol. 2011;60(6):1142–1148.
   PubMed Web of Science ®Google Scholar
• Leufgens F, Berneking V, Vogeli TA, et al. Quality of life changes >10 years following postoperative radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2019;105(2):382–388.
   PubMedGoogle Scholar
• Kopp RP, Marshall LM, Wang PY, et al. The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors. Eur Urol. 2013;64(4):672–679.
   PubMed Web of Science ®Google Scholar
• Lee JY, Daignault-Newton S, Heath G, et al. Multinational prospective study of patient-reported outcomes after prostate radiation therapy: detailed assessment of rectal bleeding. Int J Radiat Oncol Biol Phys. 2016;96(4):770–777.
   PubMed Web of Science ®Google Scholar
• Thor M, Apte A, Deasy JO, et al. Dose/volume-response relations for rectal morbidity using planned and simulated motion-inclusive dose distributions. Radiother Oncol. 2013;109(3):388–393.
   PubMed Web of Science ®Google Scholar
• Berlin A, Cho E, Kong V, et al. Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. Pract Radiat Oncol. 2015;5(5):e473–e482.
   PubMedGoogle Scholar
• Bruner DW, Hunt D, Michalski JM, et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer. 2015;121(14):2422–2430.
   PubMed Web of Science ®Google Scholar
• Son CH, Melotek JM, Liao C, et al. Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol. 2016;6(5):e179–e185.
   PubMed Web of Science ®Google Scholar
• Moinpour CM, Hayden KA, Unger JM, et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol. 2008;26(1):112–120.
   PubMed Web of Science ®Google Scholar
• Cremers RG, van Lin EN, Gerrits WL, et al. Efficacy and tolerance of salvage radiotherapy after radical prostatectomy, with emphasis on high-risk patients suited for adjuvant radiotherapy. Radiother Oncol. 2010;97(3):467–473.
   PubMed Web of Science ®Google Scholar
• Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology. 2001;58(2 Suppl 1):94–100.
   PubMedGoogle Scholar
• Bylow K, Dale W, Mustian K, et al. Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology. 2008;72(2):422–427.
   PubMed Web of Science ®Google Scholar